Dr. Robert S. Langer Joins HealthCare Royalty Partners Strategic Advisory Board
STAMFORD, Conn., Jan. 4, 2013 /PRNewswire/ -- HealthCare Royalty Partners ("HC Royalty"), a global healthcare investment firm, today announced that Dr. Robert S. Langer, Institute Professor and Founder of the Langer Lab at the Massachusetts Institute of Technology, has joined its Strategic Advisory Board.
"Dr. Langer's lab at M.I.T has been at the front lines of turning discoveries into a range of drugs and drug delivery systems. We are honored to have him serve as one of our advisors," commented Todd Davis, Founding Managing Director at HC Royalty.
Dr. Langer served as a member of the United States Food and Drug Administration's SCIENCE Board, the FDA's highest advisory board, from 1995 - 2002 and as its Chairman from 1999-2002. He has helped start 25 companies, and more than 250 pharmaceutical, chemical, biotechnology and medical device companies have licensed or sublicensed Langer Lab patents. Over the course of his tenured career, Dr. Langer has received over 210 major awards including the 2013 Wolf Prize in Chemistry, which is considered the Israel Nobel Prize and the U.S. National Medal of Technology and Innovation.
"HC Royalty has played a critical role to bring new and differentiated products to market and I look forward to working with the senior team to evaluate many more promising discoveries," stated Dr. Langer.
About HealthCare Royalty Partners
HealthCare Royalty Partners is a global healthcare investment firm focused on providing financing solutions to healthcare companies and royalty owners with interests in approved pharmaceutical and medical device products. The firm's senior investment team has participated in 45 royalty financings valued at over $2 billion over the past decade. For more information, visit www.healthcareroyalty.com/.
Synthetic Royalty® is a registered trademark of HealthCare Royalty Management, LLC.
SOURCE HealthCare Royalty Partners